Fucoxanthin Exerts Anti-Tumor Activity on Canine Mammary Tumor Cells via Tumor Cell Apoptosis Induction and Angiogenesis Inhibition

Jang, Hyuk Jai; Choi, Jawun; Park, Jeong-Ki; Won, Gayeon; Seol, Jae‐Won

doi:10.3390/ani11061512

Cited by 15 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MMPs play a pivotal role in assisting tumor cells' invasion and migration [129], while the activities of MMPs are specifically adjusted by tissue inhibitors' TIMPs [128]. In addition, Fx inhibits the migratory ability of CMT-U27 cells and HUVECs in both time-and dose-dependent manners [97]. These results suggest the inhibitory effects of Fx on BC cell migration and invasion.…”

Section: Anti-metastatic Effectsmentioning

confidence: 92%

“…Jang also reported that Fx possesses anti-angiogenic activity that is due to its ability to reduce the microvascular sprouting of HUVEC by 25% [97]. Moreover, the tubule formation of HUVECs is significantly inhibited after treatments.…”

Section: Anti-angiogenic Effectsmentioning

confidence: 93%

“…In addition, Rwigemera believes that Fx and Fxol inhibit the viability of estrogen-resistant BC cells by down-regulating the SOX9 phosphorylation. It is interesting to note that Fx can also reduce cell viability of CMT-U27 cells, which are canine mammary tumor cells, in a dose-dependent manner [97].…”

Section: Anti-proliferative Effectmentioning

confidence: 99%

“…Fx can also induce apoptosis in CMT-U27 cells, which are canine mammary tumor cells, in a dose-dependent manner [97]. Apoptosis is precisely controlled by caspase3, caspase 7, caspase 8 activities.…”

Section: Apoptotic Effectmentioning

confidence: 99%

See 3 more Smart Citations

Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer

Lau

Kwan

2022

Marine Drugs

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most common cancers diagnosed and the leading cause of cancer-related death in women. Although there are first-line treatments for BC, drug resistances and adverse events have been reported. Given the incidence of BC keeps increasing, seeking novel therapeutics is urgently needed. Fucoxanthin (Fx) is a dietary carotenoid commonly found in seaweeds and diatoms. Both in vitro and in vivo studies show that Fx and its deacetylated metabolite fucoxanthinol (Fxol) inhibit and prevent BC growth. The NF-κB signaling pathway is considered the major pathway contributing to the anti-proliferation, anti-angiogenesis and pro-apoptotic effects of Fx and Fxol. Other signaling molecules such as MAPK, MMP2/9, CYP and ROS are also involved in the anti-cancer effects by regulating the tumor microenvironment, cancer metastasis, carcinogen metabolism and oxidation. Besides, Fx also possesses anti-obesity effects by regulating UCP1 levels and lipid metabolism, which may help to reduce BC risk. More importantly, mounting evidence demonstrates that Fx overcomes drug resistance. This review aims to give an updated summary of the anti-cancer effects of Fx and summarize the underlying mechanisms of action, which will provide novel strategies for the development of Fx as an anti-cancer therapeutic agent.

show abstract

Section: Anti-metastatic Effectsmentioning

confidence: 92%

Section: Anti-angiogenic Effectsmentioning

confidence: 93%

Section: Anti-proliferative Effectmentioning

confidence: 99%

Section: Apoptotic Effectmentioning

confidence: 99%

See 2 more Smart Citations

Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer

Lau

Kwan

2022

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…Compared to the other groups, siTwist/FX@HES-CH treatment resulted in the highest TUNEL and lowest Ki67 expression in tumor tissues, indicating an increase in apoptotic cell death and a signi cant decrease in tumor proliferation. Furthermore, FX exhibits the ability to suppress the differentiation of endothelial progenitor cells into endothelial cells, which involves the formation of new blood vessels [70,71]. Meanwhile, Twist overexpression in breast cancer cells could also induce abnormal angiogenesis [72,73].…”

Section: In Vivo Biodistribution Of Nanoparticlesmentioning

confidence: 99%

Co-delivery of fucoxanthin and Twist siRNA using hydroxyethyl starch-cholesterol self-assembled polymer nanoparticles for triple-negative breast cancer synergistic therapy

Tang

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Triple-negative breast cancer (TNBC) represents the most aggressive subtype of breast cancer with an extremely dismal prognosis and few treatment options. As a desmoplastic tumor, tumor cells are girdled by stroma composed of tumor-associated fibroblasts (CAFs) and their secreted stromal components. The rapidly proliferating tumor cells, together with the tumor stroma, exert additional solid tissue pressure on tumor vasculature and surrounding tissues, severely obstructing therapeutic agent from deep intratumoral penetration, and resulting in tumor metastasis and treatment resistance. Fucoxanthin (FX), a xanthophyll carotenoid abundant in marine algae, has attracted widespread attention as a promising alternative candidate for tumor prevention and treatment. Twist is a pivotal regulator of epithelial to mesenchymal transition (EMT), and its depletion has proven to sensitize antitumor drugs, inhibit metastasis, reduce CAFs activation and the following interstitial deposition, increase tumor perfusion, and allow more drugs to be delivered across the tumor stroma. Results: Herein, our studies proposed a novel self-assembled polymer nanoparticle (siTwist/FX@HES-CH NPs) based on the amino-modified hydroxyethyl starch (HES-NH2) grafted with hydrophobic segment cholesterol (CH). Systematic studies demonstrated that the co-delivery strategy of natural product FX and nucleic acid drug Twist siRNA (siTwist) could not only synergistically kill tumor cells, but also inhibit the CAFs activation and extracellular matrix synthesis. Loose tumor stroma further facilitated transvascular transport and deep penetration of nanoparticles, obviously alleviating the primary tumor burden and inhibiting lung metastasis. Conclusions: This dually functional nanomedicine that targets both tumor cells and tumor microenvironment (TME) could form a potent anti-TNBC therapeutic cyclical feedback loop, providing a new paradigm for TNBC treatment.

show abstract

Natural products‐based antiangiogenic agents: New frontiers in cancer therapy

Azevedo,

Ferreira,

Peña‐Corona

et al. 2024

Food Frontiers

View full text Add to dashboard Cite

Angiogenesis, vital for tumor growth and metastasis, is a promising target in cancer therapy. Natural compounds offer potential as antiangiogenic agents with reduced toxicity. This review provides a comprehensive overview of natural product‐based antiangiogenic therapies, focusing on molecular mechanisms and therapeutic potential. A systematic search identified relevant articles from 2019 to 2023. Various natural compounds, including polyphenols, terpenes, alkaloids, cannabinoids, omega‐3 fatty acids, polysaccharides, proteins, and carotenoids, were investigated for their antiangiogenic properties. Challenges such as dose standardization, routes of administration, and potential side effects remain. Further studies, including in‐depth animal models and human epidemiological studies, must elucidate clinical efficacy and safety. Synergistic effects with current antiangiogenic therapies, such as bevacizumab and tyrosine kinase inhibitors, should be explored. Additionally, the potential hormone‐dependent effects of compounds like genistein highlight the need for safety evaluation. In conclusion, natural products hold promise as adjunctive therapies to conventional antineoplastic drugs in modulating angiogenesis in cancer. However, robust clinical trials are needed to validate preclinical findings and ensure safety and efficacy.

show abstract

Fucoxanthin Exerts Anti-Tumor Activity on Canine Mammary Tumor Cells via Tumor Cell Apoptosis Induction and Angiogenesis Inhibition

Cited by 15 publications

References 38 publications

Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer

Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer

Co-delivery of fucoxanthin and Twist siRNA using hydroxyethyl starch-cholesterol self-assembled polymer nanoparticles for triple-negative breast cancer synergistic therapy

Natural products‐based antiangiogenic agents: New frontiers in cancer therapy

Contact Info

Product

Resources

About